Structures by: Ahabchane N. H.
Total: 9
2-(2-Oxo-1,3-oxazolidin-3-yl)ethyl 2-[2-(2-oxo-1,3-oxazolidin-3-yl)ethoxy]quinoline-4-carboxylate
C20H21N3O7
Acta Crystallographica Section E (2021) 77, 1 28-33
a=6.0686(5)Å b=19.2791(15)Å c=16.3795(13)Å
α=90° β=94.185(4)° γ=90°
Hexyl 1-hexyl-2-oxo-1,2-dihydroquinoline-4-carboxylate
C22H31NO3
Acta Crystallographica Section E (2020) 76, 5 642-645
a=17.6928(7)Å b=13.2512(5)Å c=8.5916(3)Å
α=90° β=90.184(2)° γ=90°
N-Éthyl-N-[2-(3-phénylisoxazol-5-ylméthylamino)phényl]benzylacétamide
C27H27N3O2
Acta Crystallographica Section E (2002) 58, 11 o1304-o1305
a=9.8250(10)Å b=10.9990(10)Å c=12.0950(10)Å
α=91.560(10)° β=109.220(10)° γ=109.370(10)°
4-Phenyl-2-(2-pyridylmethylsulfanyl)-3<i>H</i>-1,5-benzodiazepine
C21H17N3S
Acta Crystallographica Section E (2007) 63, 7 o3306-o3306
a=14.2995(3)Å b=8.7004(2)Å c=14.3851(4)Å
α=90.00° β=103.3370(10)° γ=90.00°
1-Allyl-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-2-one
C18H16N2O
Acta Crystallographica Section E (2010) 66, 6 o1277
a=11.4863(3)Å b=6.0053(2)Å c=20.3667(5)Å
α=90.00° β=93.5250(10)° γ=90.00°
4-Phenyl-9,12,15-trioxa-1,5,6,18- tetraazatetracyclo[16.6.1.0^2,6^.0^19,24^]pentaconta-2,4,19,21,23- pentaen-25-one
C24H26N4O4
Acta Crystallographica Section E (2009) 65, 10 o2493
a=13.3480(10)Å b=15.7850(10)Å c=11.0070(10)Å
α=90° β=102.6810(10)° γ=90°
Ethyl 2-(2-oxo-4-phenyl-2,3-dihydro-1<i>H</i>-1,5-benzodiazepin-1-yl)acetate
C19H18N2O3
Acta Crystallographica Section E (2010) 66, 8 o2070
a=12.5198(4)Å b=11.7911(3)Å c=11.2058(3)Å
α=90.00° β=97.843(2)° γ=90.00°
1-[2-(2-Oxo-1,3-oxazolidin-3-yl)ethyl]-4-phenyl-1<i>H</i>- 1,5-benzodiazepin-2(3<i>H</i>)-one
C20H19N3O3
Acta Crystallographica Section E (2010) 66, 8 o2080
a=9.0163(5)Å b=11.6671(6)Å c=16.2019(8)Å
α=90.00° β=90.00° γ=90.00°
2-(Benzylsulfanyl)-4-phenyl-3<i>H</i>-1,5-benzodiazepine
C22H18N2S
Acta Crystallographica Section E (2007) 63, 7 o3305-o3305
a=8.9633(2)Å b=8.4904(2)Å c=23.1997(5)Å
α=90.00° β=92.2060(10)° γ=90.00°